Abstract Library

#4222 Quali-NET: A prospective study on patient-reported quality of life in neuroendocrine neoplasms

Introduction: Neuroendocrine neoplasms of the lung (LNEN) or gastro-enteropancreatic tract (GEPNEN) are typically slow-growing, leading to longer overall survival, and resembling chronic illnesses. Therefore, focus on quality of life (QoL) is crucial. While brief studies have been done, comprehensive, long-term studies are needed.

Conference:

Presenting Author: Islam O

Authors: Islam O, Depauw L, van der Massen I, Simoens M, Galdermans D,

Keywords: GEP-NEN, LNEN, Quality of life, Longitudinal data,

#3910 Integrative molecular analysis of lung neuroendocrine neoplasms with different Ki-67 indices identifies a molecular transition group between low- and high-grade neoplasms

Introduction: In the 2021 World Health Organization (WHO) classification of lung cancers, lung neuroendocrine neoplasms (LNENs) are classified as low-grade, intermediate-grade and high-grade based on mitotic count but not Ki-67 index, as for GEP-NENs.

Conference:

Presenting Author:

Authors: Simbolo M, Centonze G, Ali G, Grillo F, Sabella G,

Keywords: lung neuroendocrine tumor, NET grade 3, next generation sequencing, transcriptomics,

#3235 A molecular map of lung neuroendocrine neoplasms

Introduction: Lung neuroendocrine neoplasms (LNEN) are understudied cancers because of their rarity, and the sample sizes of the genomic studies are limited. Recently, we performed the first multi-omic characterization of atypical carcinoids, unveiling the existence of the supra-carcinoids and providing the missing pieces for a complete molecular characterization of LNEN.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Mathian E, Gabriel A, Mangiante L, Voegele C, Cahais V,

Keywords: carcinoid, lung cancer, neuroendocrine neoplasm, rare cancers, omics, tumor map,

#3030 Targeting CXCR4 and Thioredoxin Reductase in Theranostics of Atypical Carcinoid and Neuroendocrine Carcinoma

Introduction: Atypical carcinoid and small cell lung cancer (SCLC) are currently incurable. There is thus a critical need for new diagnostic and therapeutic strategies for lung neuroendocrine neoplasms (LNEN). Chemokine receptor 4 (CXCR4), a G protein coupled receptor and theranostic target, plays a crucial role in metastases of LNEN. We hypothesize combination of thioredoxin reductase (TR) inhibitor represents a metabolic strategy to enhance cytotoxicity in peptide-receptor radionuclide therapy (PRRT) of LNEN.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Liu D

Authors: Liu D, Fath M, Robles Planells C, Balk E, Bellizzi A,

Keywords: CXCR4, thioredoxin reductase inhibitor, theranostics, atypical carcinoid, small cell lung cancer,